company background image
MEM logo

Memphasys CHIA:MEM Stock Report

Last Price

AU$0.005

Market Cap

AU$7.2m

7D

-16.7%

1Y

-58.3%

Updated

23 Dec, 2024

Data

Company Financials

Memphasys Limited

CHIA:MEM Stock Report

Market Cap: AU$7.2m

MEM Stock Overview

Develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. More details

MEM fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the Australian market

Does not have a meaningful market cap (A$7M)

Earnings have declined by 33.4% per year over past 5 years

Makes less than USD$1m in revenue (A$1M)

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Memphasys Limited Competitors

Genetic Technologies

ASX:GTG

AU$5.7m

OncoSil Medical

ASX:OSL

AU$31.5m

Cryosite

ASX:CTE

AU$41.5m

Proteomics International Laboratories

ASX:PIQ

AU$83.8m

Price History & Performance

Summary of share price highs, lows and changes for Memphasys
Historical stock prices
Current Share PriceAU$0.005
52 Week HighAU$0.015
52 Week LowAU$0.004
Beta1.03
1 Month Change-16.67%
3 Month Change-37.50%
1 Year Change-58.33%
3 Year Change-94.38%
5 Year Change-90.20%
Change since IPO-96.97%

Recent News & Updates

Recent updates

Shareholder Returns

MEMAU Life SciencesAU Market
7D-16.7%2.0%-2.7%
1Y-58.3%13.8%6.5%

Return vs Industry: MEM underperformed the Australian Life Sciences industry which returned 13.8% over the past year.

Return vs Market: MEM underperformed the Australian Market which returned 6.5% over the past year.

Price Volatility

Is MEM's price volatile compared to industry and market?
MEM volatility
MEM Average Weekly Movement28.8%
Life Sciences Industry Average Movement8.9%
Market Average Movement8.0%
10% most volatile stocks in AU Market16.8%
10% least volatile stocks in AU Market3.1%

Stable Share Price: MEM's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: MEM's weekly volatility (29%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2006n/aDavid Aliwww.memphasys.com

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company primarily develops Felix, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid oxidative stress assay; and AI-Port.

Memphasys Limited Fundamentals Summary

How do Memphasys's earnings and revenue compare to its market cap?
MEM fundamental statistics
Market capAU$7.23m
Earnings (TTM)-AU$4.44m
Revenue (TTM)AU$1.09m

8.0x

P/S Ratio

-2.0x

P/E Ratio

Is MEM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MEM income statement (TTM)
RevenueAU$1.09m
Cost of RevenueAU$115.46k
Gross ProfitAU$974.38k
Other ExpensesAU$5.42m
Earnings-AU$4.44m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0031
Gross Margin89.41%
Net Profit Margin-407.58%
Debt/Equity Ratio64.5%

How did MEM perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:42
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Memphasys Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution